These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29493381)

  • 21. Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
    Atsumi T; Fujio K; Yamaoka K; Tomobe M; Kuroyanagi K; Kameda H
    Mod Rheumatol; 2018 Sep; 28(5):780-788. PubMed ID: 29251032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Choice of the most appropriate biological disease-modifying anti-rheumatic drug for injection spacing: results from a multicentre observational study.
    Matsuno H; Katayama K; Funahashi K; Saitoh M; Matsubara T
    Clin Exp Rheumatol; 2020; 38(3):398-404. PubMed ID: 31287398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry.
    Kawabe A; Nakano K; Kubo S; Asakawa T; Tanaka Y
    Arthritis Res Ther; 2020 Jun; 22(1):136. PubMed ID: 32513309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab.
    Matsuno H; Katayama K
    Mod Rheumatol; 2017 Mar; 27(2):246-251. PubMed ID: 27550060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.
    Iannone F; Ferraccioli G; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Gorla R; Bazzani C; Govoni M; Farina I; Gremese E; Carletto A; Giollo A; Galeazzi M; Foti R; Bianchino L; La Grasta L; Lapadula G
    Clin Rheumatol; 2018 Feb; 37(2):315-321. PubMed ID: 28980085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study.
    Nakamura S; Suzuki K; Iijima H; Hata Y; Lim CR; Ishizawa Y; Kameda H; Amano K; Matsubara K; Matoba R; Takeuchi T
    Arthritis Res Ther; 2016 Jul; 18():159. PubMed ID: 27435242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011 : A retrospective analysis of 72% of the population.
    Stamm TA; Reichardt B; Zwerina J; Ritschl V; Nell-Duxneuner V
    Wien Klin Wochenschr; 2018 Apr; 130(7-8):230-237. PubMed ID: 29445863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients.
    Tan BE; Lim AL; Kan SL; Lim CH; Tsang EEL; Ch'ng SS; Mohd Noor N; Mohd Jamid N; Teh CL; Joshua Thundyil R; Loh YL; Chong HC; Ong SG; Mohamed Ismail A; Lee YYL; Gun SC
    Rheumatol Int; 2017 Oct; 37(10):1719-1725. PubMed ID: 28695274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
    Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trend in prescription and treatment retention of molecular-targeted drugs in 121,131 Japanese patients with rheumatoid arthritis: A population-based real-world study.
    Takabayashi K; Ando F; Ikeda K; Fujita S; Nakajima H; Hanaoka H; Suzuki T
    Mod Rheumatol; 2022 Aug; 32(5):857-865. PubMed ID: 34907436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
    Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
    Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Terabe K; Takahashi N; Asai S; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Ishikawa H; Hanabayashi M; Hattori Y; Suzuki M; Kishimoto K; Ohashi Y; Imaizumi T; Imagama S; Kojima T
    Mod Rheumatol; 2023 Mar; 33(2):292-301. PubMed ID: 35289372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real-world setting in Taiwan.
    Chen KH; Li KJ; Fang YF; Hsieh SC; Chen YC; Lee CS; Luo SF; Cheng TT; Tsai WC; Lo YC; Lan JL
    Int J Rheum Dis; 2024 Jul; 27(7):e15199. PubMed ID: 39010815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.
    Ishiguro N; Atsumi T; Harigai M; Mimori T; Nishimoto N; Sumida T; Takeuchi T; Tanaka Y; Nakasone A; Takagi N; Yamanaka H
    Mod Rheumatol; 2017 Mar; 27(2):217-226. PubMed ID: 27414105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study.
    Lampropoulos CE; Orfanos P; Bournia VK; Karatsourakis T; Mavragani C; Pikazis D; Manoussakis MN; Tzioufas AG; Moutsopoulos HM; Vlachoyiannopoulos PG
    Clin Exp Rheumatol; 2015; 33(2):216-24. PubMed ID: 25664400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study.
    Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
    Semin Arthritis Rheum; 2018 Dec; 48(3):399-405. PubMed ID: 29673963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
    Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
    Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.